News
PRPO
17.35
-6.17%
-1.14
Weekly Report: what happened at PRPO last week (1109-1113)?
Weekly Report · 4d ago
Precipio Earnings Call Signals Cash Strength and Growth Ambition
TipRanks · 5d ago
Precipio (PRPO) Q3 2026 Earnings Call Transcript
The Motley Fool · 11/11 10:28
Precipio Q3 2026 Earnings Call Transcript
Benzinga · 11/10 22:04
Precipio reports Q3 results
Seeking Alpha · 11/10 21:40
Precipio Q3 EPS $0.00, Sales $7.331M Up From $6.767M YoY
Benzinga · 11/10 21:32
Press Release: Precipio Announces Q3-2026 Financial Results
Dow Jones · 11/10 21:15
Here are the major earnings after the close Tuesday
Seeking Alpha · 11/10 15:00
Weekly Report: what happened at PRPO last week (1102-1106)?
Weekly Report · 11/09 09:48
Weekly Report: what happened at PRPO last week (1026-1030)?
Weekly Report · 11/02 09:48
Precipio, Inc. to Host Q3-2026 Shareholder Update Call on November 10th, 2026
NASDAQ · 10/30 01:52
Precipio Announces Q3 2026 Shareholder Update Call
TipRanks · 10/29 21:13
Weekly Report: what happened at PRPO last week (1019-1023)?
Weekly Report · 10/26 09:48
Weekly Report: what happened at PRPO last week (1012-1016)?
Weekly Report · 10/19 09:48
Precipio: Management Dreams Big, Institutions Have A Toe In
Seeking Alpha · 10/12 14:33
Weekly Report: what happened at PRPO last week (1005-1009)?
Weekly Report · 10/12 09:51
Weekly Report: what happened at PRPO last week (0928-1002)?
Weekly Report · 10/05 09:51
Weekly Report: what happened at PRPO last week (0921-0925)?
Weekly Report · 09/28 09:48
PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?
NASDAQ · 09/22 17:16
Weekly Report: what happened at PRPO last week (0914-0918)?
Weekly Report · 09/21 09:48
More
Webull provides a variety of real-time PRPO stock news. You can receive the latest news about Precipio Inc through multiple platforms. This information may help you make smarter investment decisions.
About PRPO
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.